Consolidated Statements of Changes in Shareholders' Deficit - USD ($) shares in Millions, $ in Millions		Total	Cumulative effect adjustment	Common Stock	Additional Paid-in Capital	Retained Earnings (Losses)	Retained Earnings (Losses) Cumulative effect adjustment	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2019				770.0					319.9
Beginning balance at Dec. 31, 2019		$ (983.8)	$ (2.0)	$ 192.6	$ 2,321.2	$ 2,138.9	$ (2.0)	$ (1,040.0)	$ (4,603.3)	$ 6.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(171.9)				(171.0)				(0.9)
Other comprehensive income (loss)		(104.5)						(104.3)		(0.2)
Conversion of Series C convertible preferred stock	[1]	486.8				(710.8)			$ 1,197.6
Conversion of Series C convertible preferred stock (in shares)	[1]								(87.0)
Exercise/ vesting/ expense of share-based compensation		(9.9)		$ (0.2)	(9.7)
Exchange of common stock (in shares)	[2]			(770.0)					(232.9)
Exchange of common stock	[2]	0.0		$ (192.4)	(1,788.1)	(1,425.2)			$ 3,405.7
Ending balance (in shares) at Mar. 31, 2020				0.0					0.0
Ending balance at Mar. 31, 2020		(785.3)		$ 0.0	523.4	(170.1)		(1,144.3)	$ 0.0	5.7
Beginning balance (in shares) at Dec. 31, 2019				770.0					319.9
Beginning balance at Dec. 31, 2019		(983.8)	$ (2.0)	$ 192.6	2,321.2	2,138.9	$ (2.0)	(1,040.0)	$ (4,603.3)	6.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(298.9)
Other comprehensive income (loss)		(126.9)
Ending balance (in shares) at Sep. 30, 2020	[3]			0.0					0.0
Ending balance at Sep. 30, 2020	[3]	(929.0)		$ 0.0	527.7	(294.3)		(1,166.9)	$ 0.0	4.5
Beginning balance (in shares) at Mar. 31, 2020				0.0					0.0
Beginning balance at Mar. 31, 2020		(785.3)		$ 0.0	523.4	(170.1)		(1,144.3)	$ 0.0	5.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(93.5)				(92.8)				(0.7)
Other comprehensive income (loss)		(1.5)						(1.5)
Exercise/ vesting/ expense of share-based compensation		0.8			0.8
Ending balance (in shares) at Jun. 30, 2020				0.0					0.0
Ending balance at Jun. 30, 2020		(879.5)		$ 0.0	524.2	(262.9)		(1,145.8)	$ 0.0	5.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(33.5)				(32.8)				(0.7)
Gain on common control transaction		1.4				1.4
Other comprehensive income (loss)		(20.9)						(21.1)		0.2
Exercise/ vesting/ expense of share-based compensation		3.5			3.5
Ending balance (in shares) at Sep. 30, 2020	[3]			0.0					0.0
Ending balance at Sep. 30, 2020	[3]	(929.0)		$ 0.0	527.7	(294.3)		(1,166.9)	$ 0.0	4.5
Beginning balance (in shares) at Dec. 31, 2020				0.0
Beginning balance at Dec. 31, 2020		(867.2)		$ 0.0	622.8	(360.5)		(1,133.8)		4.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(63.9)				(63.6)				(0.3)
Other comprehensive income (loss)		(43.3)						(43.3)
Exercise/ vesting/ expense of share-based compensation		0.6			0.6
Ending balance (in shares) at Mar. 31, 2021				0.0
Ending balance at Mar. 31, 2021		(973.8)		$ 0.0	623.4	(424.1)		(1,177.1)		4.0
Beginning balance (in shares) at Dec. 31, 2020				0.0
Beginning balance at Dec. 31, 2020		(867.2)		$ 0.0	622.8	(360.5)		(1,133.8)		4.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(169.1)
Other comprehensive income (loss)		(19.9)
Ending balance (in shares) at Sep. 30, 2021	[4]			0.0
Ending balance at Sep. 30, 2021	[4]	(898.5)		$ 0.0	632.1	(379.8)		(1,153.5)		2.7
Beginning balance (in shares) at Mar. 31, 2021				0.0
Beginning balance at Mar. 31, 2021		(973.8)		$ 0.0	623.4	(424.1)		(1,177.1)		4.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(62.1)				(61.6)				(0.5)
Other comprehensive income (loss)		32.2						32.1		0.1
Exercise/ vesting/ expense of share-based compensation		4.2			4.2
Ending balance (in shares) at Jun. 30, 2021	[4]			0.0
Ending balance at Jun. 30, 2021	[4]	(999.5)		$ 0.0	627.6	(485.7)		(1,145.0)		3.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of Avon Luxembourg	[5]	148.4				148.4
Net loss		(43.1)				(42.5)				(0.6)
Other comprehensive income (loss)		(8.8)						(8.5)		(0.3)
Exercise/ vesting/ expense of share-based compensation		4.5			4.5
Ending balance (in shares) at Sep. 30, 2021	[4]			0.0
Ending balance at Sep. 30, 2021	[4]	$ (898.5)		$ 0.0	$ 632.1	$ (379.8)		$ (1,153.5)		$ 2.7

[1] On December 30, 2019, an affiliate of Cerberus Capital Management, L.P. ("Cerberus") elected to convert 435,000 shares of Series C Preferred Stock into 87,000,000 shares of the Company’s common stock, par value U.S.$0.25 per share, conditioned on the Conversion Condition (as defined below).

[2] In January 2020, subsequent to the Transaction, the Company restated its certificate of incorporation to effect a change in capitalization of the Company by changing the number of authorized shares of common stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, were common stock and (ii) 25,000,000 shares, par value $1.00 per share, were preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result of the Transaction, all of the issued and outstanding common stock of the Company, being 550,890,788, were canceled and converted. See Note 17, Mergers with Natura Cosméticos S.A.

[3] The number of shares of Common Stock (par value $0.01 per share) outstanding at September 30, 2020 was 101.34.

[4] The number of shares of Common Stock (par value $0.01 per share) outstanding at September 30, 2021 was 101.34.

[5] On July 1, 2021, the Company sold Avon Luxembourg Holdings S.à r.l. and its subsidiaries ("Avon Luxembourg"), including our Mexican business, to a subsidiary of Natura &Co Holding S.A. for $150. The sale was accounted for as a transaction under common control in accordance with ASC805 - Business Combinations, with the resulting gain of $148, representing the difference between the proceeds, the net assets of Avon Luxembourg on the date of sale, and the cumulative foreign currency translation adjustment, taken directly to Retained Earnings.